ATE414151T1 - Antikörper gegen eotaxin und deren verwendung - Google Patents

Antikörper gegen eotaxin und deren verwendung

Info

Publication number
ATE414151T1
ATE414151T1 AT01907990T AT01907990T ATE414151T1 AT E414151 T1 ATE414151 T1 AT E414151T1 AT 01907990 T AT01907990 T AT 01907990T AT 01907990 T AT01907990 T AT 01907990T AT E414151 T1 ATE414151 T1 AT E414151T1
Authority
AT
Austria
Prior art keywords
eotaxin
antibodies
cat
specific binding
binding members
Prior art date
Application number
AT01907990T
Other languages
English (en)
Inventor
Tristan Vaughan
Alison Wilton
Stephen Smith
Sarah Main
Original Assignee
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech
Application granted granted Critical
Publication of ATE414151T1 publication Critical patent/ATE414151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01907990T 2000-03-03 2001-03-02 Antikörper gegen eotaxin und deren verwendung ATE414151T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18724600P 2000-03-03 2000-03-03

Publications (1)

Publication Number Publication Date
ATE414151T1 true ATE414151T1 (de) 2008-11-15

Family

ID=22688187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907990T ATE414151T1 (de) 2000-03-03 2001-03-02 Antikörper gegen eotaxin und deren verwendung

Country Status (14)

Country Link
US (6) US7323311B2 (de)
EP (1) EP1259615B1 (de)
JP (1) JP5198704B2 (de)
AT (1) ATE414151T1 (de)
AU (1) AU778392B2 (de)
BR (1) BRPI0108923B8 (de)
CA (1) CA2401342C (de)
DE (1) DE60136527D1 (de)
GB (1) GB2361704C (de)
IL (2) IL151499A0 (de)
MX (1) MXPA02008472A (de)
NO (1) NO20024179L (de)
NZ (1) NZ521182A (de)
WO (1) WO2001066754A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
ES2732276T3 (es) 2001-08-23 2019-11-21 Rsr Ltd Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
JP2009510046A (ja) 2005-09-30 2009-03-12 メドイミューン・リミテッド インターロイキン−１３抗体組成物
CN101443360B (zh) 2006-03-27 2013-11-27 医学免疫有限公司 Gm-csf受体结合元件
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
US8176867B2 (en) 2009-05-28 2012-05-15 Richard J. A. Gayton Watercraft immobilizing system
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
NZ736026A (en) 2015-03-31 2023-02-24 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
KR102499438B1 (ko) 2016-06-02 2023-02-14 메디뮨 리미티드 알파-시누클레인에 대한 항체 및 이의 용도
WO2017212488A1 (en) * 2016-06-06 2017-12-14 Hadasit Medical Research Service And Development Ltd. Anti-eotaxin for immunoprotection and hepatoprotection
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
TWI861073B (zh) * 2019-03-21 2024-11-11 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
ATE243747T1 (de) * 1991-07-15 2003-07-15 Wellcome Found Herstellung von antikörpern
IL103758A (en) 1991-12-13 1998-07-15 Akzo Nv Tumor specific monoclonal antibodies
CA2171761C (en) * 1993-09-14 2011-11-15 Timothy John Williams Eotaxin: eosinophil chemotactic cytokine
US6403782B1 (en) * 1995-06-22 2002-06-11 President And Fellows Of Harvard College Nucleic acid encoding eotaxin
US7265201B1 (en) 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
WO1997012914A1 (en) 1995-10-05 1997-04-10 Shionogi & Co., Ltd. Novel human cc chemokine
WO1999010534A1 (en) * 1997-08-22 1999-03-04 Center For Blood Research, Inc. Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP4113670B2 (ja) * 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1212422B1 (de) 1999-08-24 2007-02-21 Medarex, Inc. Humane antikörper gegen ctla-4 und deren verwendungen
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US6946546B2 (en) * 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
GB2361704A (en) 2001-10-31
MXPA02008472A (es) 2004-03-26
CA2401342A1 (en) 2001-09-13
US20120270265A1 (en) 2012-10-25
GB0105237D0 (en) 2001-04-18
EP1259615B1 (de) 2008-11-12
NO20024179L (no) 2002-11-01
US20140294857A1 (en) 2014-10-02
DE60136527D1 (de) 2008-12-24
NZ521182A (en) 2004-11-26
IL151499A (en) 2010-06-30
US9284589B2 (en) 2016-03-15
US20210277103A1 (en) 2021-09-09
AU778392B2 (en) 2004-12-02
US7323311B2 (en) 2008-01-29
US20080182319A1 (en) 2008-07-31
BR0108923A (pt) 2003-04-22
CA2401342C (en) 2010-08-03
US8715961B2 (en) 2014-05-06
BRPI0108923B8 (pt) 2021-05-25
GB2361704B (en) 2002-04-10
IL151499A0 (en) 2003-04-10
JP5198704B2 (ja) 2013-05-15
WO2001066754A1 (en) 2001-09-13
US8067564B2 (en) 2011-11-29
NO20024179D0 (no) 2002-09-02
US20160257741A1 (en) 2016-09-08
EP1259615A1 (de) 2002-11-27
AU3585201A (en) 2001-09-17
JP2003528598A (ja) 2003-09-30
BRPI0108923B1 (pt) 2018-11-13
US20040014132A1 (en) 2004-01-22
GB2361704C (en) 2006-08-02
US10577413B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
ATE414151T1 (de) Antikörper gegen eotaxin und deren verwendung
LU93274I2 (fr) Elotuzumab
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
PL359854A1 (en) Antibodies to human mcp-1
CY1113489T1 (el) Αντισωμα το οποιο δεσμευει αλφα4βητα7 ιντεγκρινη και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
DE60031279D1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
DE60040301D1 (de) Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung
DE60142614D1 (de) Inität
DE60331910D1 (de) Antikörper gegen humanes cd22 und deren therapeutische und diagnostische verwendungen
EA200801065A1 (ru) Антимиостатиновые антитела
DE60328195D1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
ATE372349T1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties